IMMUNOCELLULAR THERAPEUTICS's ticker is IMUC and the CUSIP is 452536105. A total of 32 filers reported holding IMMUNOCELLULAR THERAPEUTICS in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $9,000 | -10.0% | 20,000 | 0.0% | 0.00% | – |
| Q1 2015 | $10,000 | -33.3% | 20,000 | 0.0% | 0.00% | – |
| Q4 2014 | $15,000 | -16.7% | 20,000 | 0.0% | 0.00% | – |
| Q3 2014 | $18,000 | -18.2% | 20,000 | 0.0% | 0.00% | – |
| Q2 2014 | $22,000 | -8.3% | 20,000 | 0.0% | 0.00% | – |
| Q1 2014 | $24,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Callan Capital, LLC | 393,912 | $351,000 | 0.10% |
| Ifrah Financial Services, Inc. | 18,500 | $16,000 | 0.01% |
| CHELSEA COUNSEL CO | 28,000 | $25,000 | 0.01% |
| B. Riley Wealth Management, Inc. | 8,000 | $7,000 | 0.01% |
| GSA CAPITAL PARTNERS LLP | 63,800 | $57,000 | 0.00% |
| First Allied Advisory Services, Inc. | 45,000 | $40,000 | 0.00% |
| TUDOR INVESTMENT CORP ET AL | 50,124 | $45,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 70,000 | $62,000 | 0.00% |
| Gerstein Fisher | 13,000 | $12,000 | 0.00% |
| Vantage Investment Advisors, LLC | 3,000 | $3,000 | 0.00% |